Lamivudina Aurobindo Italia

Lamivudine, the active ingredient in Lamivudina Aurobindo Italia, is a nucleoside reverse transcriptase inhibitor (NRTI) presented as a tablet for oral use. It treats HIV infection and chronic hepatitis B in appropriate patients.

GNH USA supplies Lamivudina Aurobindo Italia as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lamivudine is employed in antiretroviral therapy targeting viral replication in HIV and hepatitis B infections.

- HIV infection: reduces viral load and helps restore immune function. - Chronic hepatitis B infection: suppresses viral replication and diminishes liver inflammation. - Prevention of mother-to-child transmission of HIV: lowers the risk of vertical transmission during pregnancy and delivery.

Lamivudine may cause a range of adverse reactions.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: occasional tension-type headaches. - Fatigue: feeling of tiredness or low energy. - Diarrhea: loose stools, usually transient. - Insomnia: difficulty falling or staying asleep. - Dizziness: occasional light‑headed sensation.

Serious or Rare Side Effects: - Lactic acidosis: buildup of lactic acid, a medical emergency. - Severe hepatomegaly with steatosis: significant liver enlargement with fat accumulation. - Pancreatitis: inflammation of the pancreas, presenting with abdominal pain. - Stevens‑Johnson syndrome or toxic epidermal necrolysis: severe skin reactions. - Hypersensitivity reactions: rash, fever, and organ involvement.

Lamivudine requires careful monitoring and patient counseling.

- Monitor liver function: obtain baseline and periodic liver enzyme tests. - Assess renal function: adjust dosing in patients with impaired kidneys. - Pregnancy category B: use only if the potential benefit justifies the potential risk. - Avoid in patients with known hypersensitivity to lamivudine or any component of the formulation. - Counsel on adherence: missed doses can lead to viral resistance. - Store at ambient temperature: keep below 25°C, protect from moisture, and retain in the original packaging.

Lamivudine can interact with several other medicines.

Major Interactions (Avoid): - Didanosine: concurrent use increases the risk of pancreatitis. - Stavudine: combined use may exacerbate peripheral neuropathy. - Other NRTIs with mitochondrial toxicity: may increase risk of lactic acidosis.

Moderate Interactions (Monitor Closely): - Protease inhibitors (e.g., ritonavir): may raise lamivudine plasma levels. - Nephrotoxic agents (e.g., aminoglycosides): require renal function monitoring. - Alcohol: concurrent use may worsen liver toxicity.